About: Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.38 (-2.83%)
AUTL NASDAQ Autolus Therapeutics Ltd
Autolus Therapeutics Ltd share price
AUTL price activity
Last Price
$1.380
Change (24hr)
-0.04 USD (2.47%)
Volume
2.77M
Volume (4w avg)
-
Open
$1.44
Day Range
$1.33 - $1.45
Previous Close
$1.42
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
AUTL price performance
Delayed
04 Nov, 9:00 pm GMT+0
AUTL details
AUTL Market Signals